We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Srv5.5

Survodutide Research

Mostly mechanism / observational

13 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Survodutide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2023–2026 with a typical study size of 274 participants.

Based on 13 studies · 2 meta-analyses · 6 RCTs · 1,256 total participants

Confidence

High confidence

By outcome

Weight managementPhase-2 4.8 mg dose produced ~-14.9% mean weight loss at 46 weeks; phase-3 SYNCHRONIZE-1 confirmed ~12-13% at 76 weeks · Progressive over 24-76 weeks
Mostly mechanism / observational10 studies
Glucose & glycemic controlDose-dependent HbA1c reductions in type 2 diabetes (pooled HbA1c -0.66% vs placebo) · By 16-46 weeks
Mostly mechanism / observational7 studies
Liver fat, MASH & fibrosisIn a 48-week phase-2 MASH/fibrosis trial, histologic MASH improvement without worsening fibrosis in up to 62% (4.8 mg) vs 14% placebo; phase-3 SYNCHRONIZE-MASLD met its endpoint · By 48 weeks
Mostly mechanism / observational6 studies
Safety profile
Too few graded studies2 studies

Active research area

13 studies in the last 5 years · Latest meta-analysis: 2026

20232026

1Meta-Analysis2026

Sun XY, Jiang HL, Ma YT, Xiong TQ, Leng XY, Zhao YF · J Transl Med (2026)

View source

2Meta-Analysis2025

Xiao YJ, Yu S, Zhang YL, Chen J, Liu YQ, Liu XL · Diabetes Obes Metab (2025)

View source

3RCTn=216 · medium study2026

In plain English: In total, 84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC using the efficacy estimand (P < 0.0001; treatment regimen estimand: 68.5% versus 28.6%, respectively; P < 0.0001). Mean percentage change in body weight was -12.2% with survodutide and -1.0% with placebo using the efficacy estimand.

Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ; SYNCHRONIZE-MASLD Investigators. · Nat Med (2026)

Phase-3 double-blind RCT (n=216, randomized 2:1) of once-weekly subcutaneous survodutide 6.0 mg vs placebo over 48 weeks in adults with obesity and at-risk MASLD (MRI-PDFF/biopsy-defined)
Both co-primary endpoints met: ≥30% liver-fat (MRI-PDFF) reduction in 84.2% vs 24.3% placebo (efficacy estimand), and weight -12.2% vs -1.0% placebo
Extends the phase-2 MASH biopsy signal to a phase-3 imaging-based liver-fat endpoint

View source

4RCTn=725 · large study2026

In plain English: At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2%... in the 3.6-mg group, -13.0%... in the 6.0-mg group, and -5.4%... in the placebo group; 72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P<0.001 for all comparisons with placebo).

le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietiläinen KH, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM; SYNCHRONIZE-1 Investigators. · N Engl J Med (2026)

Phase-3 double-blind RCT (n=725) of once-weekly subcutaneous survodutide 3.6/6.0 mg vs placebo over 76 weeks in adults with obesity WITHOUT diabetes — the first reported phase-3 survodutide efficacy trial
Mean weight loss -13.0% (6.0 mg) and -12.2% (3.6 mg) vs -5.4% placebo (treatment-regimen estimand); both co-primary endpoints met
Phase-3 weight loss (~12-13%) came in below the ~14.9% top-dose phase-2 planned-treatment figure, reflecting the more conservative treatment-regimen estimand and high placebo response

View source

5RCT2024

Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E · N Engl J Med (2024)

View source

6RCT2023

Yazawa R, Ishida M, Balavarca Y, Hennige AM · Diabetes Obes Metab (2023)

View source

7RCT2024

le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM · Lancet Diabetes Endocrinol (2024)

View source

8RCT2024

Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM · Diabetologia (2024)

View source

9Review2026

In plain English: We highlight how multireceptor agonists and oral GLP-1-based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options.

Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. · Endocrine reviews (2026)

Further innovation is seen in triple agonists such as retatrutide, which targets GIP, GLP-1, and glucagon receptors to amplify metabolic effects.
Meanwhile, the emergence of orally active small-molecule GLP-1 receptor agonists like danuglipron and orforglipron, which are resistant to enzymatic degradation, marks a major advance in patient-friendly drug delivery.
This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide.

View source

10n=274 · medium study2026

In plain English: Conclusions The results of SYNCHRONIZE-JP will provide Japan-specific efficacy, safety and tolerability data for survodutide and inform its potential role in the management of obesity disease.

Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, Inoue T, Borowska L, Brueckmann M, Ogawa W, SYNCHRONIZE‐JP Trial Investigators. · Diabetes, obesity & metabolism (2026)

The primary endpoints are percentage change in body weight and achievement of body weight reduction ≥ 5% from baseline to Week 76.
Results Of 274 enrolled participants, 24.1% had T2D.
The mean age was 53.1 years; 47.8% were female, and mean BMI was 33.2 kg/m 2 .

View source

11Review2024

In plain English: Survodutide's dual agonism of the GCGR and GLP-1 R may surpass the efficacy of selective GLP-1 R agonists, demonstrating significant potential in resolving MASH and promoting fibrosis regression.

Kaya E, Yilmaz Y, Alkhouri N. · Expert Opin Investig Drugs (2024)

Review of survodutide's pharmacology, phase-1/phase-2 efficacy and safety in obesity and MASH
Frames the dual GCGR/GLP-1R mechanism as potentially superior to GLP-1 mono-agonism for MASH and fibrosis regression — an area where GLP-1 agonists alone have unproven fibrosis benefit
Notes generally manageable, primarily gastrointestinal adverse effects

View source

12Review2025

In plain English: Phase 2 trials have demonstrated weight loss up to 18.7% and HbA1c reductions up to -1.71%, outperforming semaglutide for weight outcomes while maintaining comparable glycemic efficacy... Adverse events, primarily gastrointestinal intolerance and modest heart rate increases, remain important limitations.

Arun AJ, Darji B, Baig M, Frishman WH, Aronow WS. · Cardiol Rev (2025)

Cardiometabolic-focused review summarising survodutide's broad metabolic effects across obesity, type 2 diabetes and MASH
Cites phase-2 weight loss up to 18.7% and HbA1c reductions up to -1.71%, with hepatic fat reduction and anti-inflammatory signals
Flags modest heart-rate increases and GI intolerance driving higher discontinuation than comparators as key limitations

View source

13Open-Labeln=41 · small study2024

In plain English: Survodutide is generally tolerable in people with compensated or decompensated cirrhosis, does not require pharmacokinetic-related dose adjustment, and may improve liver-related non-invasive tests, supporting its investigation for MASH-related cirrhosis.

Lawitz EJ, Fraessdorf M, Neff GW, Schattenberg JM, Noureddin M, Alkhouri N, Schmid B, Andrews CP, Takács I, Hussain SA, Fenske WK, Gane EJ, Hosseini-Tabatabaei A, Sanyal AJ, Mazo DF, Younes R. · J Hepatol (2024)

Multinational, non-randomized, open-label phase-1 trial of subcutaneous survodutide in people with Child-Pugh A/B/C cirrhosis vs matched healthy/overweight controls (single-dose cohorts n=41)
Pharmacokinetics did not require dose adjustment for cirrhosis severity; survodutide was generally tolerable including in decompensated cirrhosis
Associated reductions in liver-fat content, markers of liver fibrosis and bodyweight

View source

View in Research Library

Survodutide Research

Mostly mechanism / observational

Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.

Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Survodutide Once Weekly for the Treatment of Adults with Obesity.

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial

Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.

Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.